BGLC
BioNexus Gene Lab Corp Common stock
NASDAQ: BGLC · BASIC MATERIALS · SPECIALTY CHEMICALS
$2.02
-4.14% today
Updated 2026-06-05
Market cap
$5.56M
P/E ratio
—
P/S ratio
1.05x
EPS (TTM)
$-1.49
Dividend yield
—
52W range
$2 – $16
Volume
0.0M
BioNexus Gene Lab Corp Common stock (BGLC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
-98.9%
Most recent quarter
EPS YoY growth
-18.4%
Most recent quarter
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.1%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+3.5%
2025-11-14
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-04-14 | $-0.22 | — | $2.26 | $2.18 | -3.5% |
| 2025-12-31 | $-0.52 | — | $3.95 | $3.94 | -0.3% |
| 2025-11-14 | $-0.40 | — | $4.52 | $4.68 | +3.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.22 | — | $22842.00 | -98.9% |
| 2025-12-31 | — | $-0.52 | — | $483760.00 | -80.8% |
| 2025-09-30 | — | $-0.40 | — | $2.54M | -3.3% |
| 2025-06-30 | $0.00 | $-0.34 | — | $2.26M | +14.5% |
| 2025-03-31 | — | $-0.19 | — | $2.14M | -10.3% |
| 2024-12-31 | — | $-0.19 | — | $2.52M | +11.0% |
| 2024-09-30 | — | $-0.75 | — | $2.63M | +3.0% |
| 2024-06-30 | — | $0.11 | — | $1.97M | — |
| 2024-03-31 | — | $-0.06 | — | $2.38M | — |
| 2023-12-31 | — | $0.17 | — | $2.27M | — |
| 2023-09-30 | — | $-1.56 | — | $2.55M | — |
Frequently asked questions
Has BioNexus Gene Lab Corp Common stock beaten earnings estimates?
BioNexus Gene Lab Corp Common stock has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does BGLC stock react to earnings?
BGLC has moved an average of -0.1% the day after earnings over its last 3 reports, finishing higher after 1 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.
What is BioNexus Gene Lab Corp Common stock's revenue growth rate?
BioNexus Gene Lab Corp Common stock reported year-over-year revenue growth of -98.9% in its most recent quarter, with EPS up -18.4%. EPS outpacing revenue is operating leverage at work, meaning profit is compounding faster than sales.